Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapy.

ABSTRACT:

Purpose

To compare the hazard of age-related macular degeneration (AMD) among non-diabetic, weight loss-eligible adults prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide or liraglutide) versus other weight loss pharmacotherapies (OWL; phentermine, orlistat, setmelanotide, phentermine-topiramate, or bupropion-naltrexone).

Design

Retrospective cohort study.

Participants

Adults ≥ 50 years without diabetes meeting criteria for weight loss pharmacotherapy and prescribed GLP-1 RAs or OWL medications. Before matching, 60 336 patients were included in the GLP-1 RA group and 21 609 in the OWL cohort; after matching, 20 959 patients remained in each cohort.

Methods

Cohorts were constructed using deidentified data from the TriNetX Research Netwo

SUBMITTER: Myers WK 

PROVIDER: S-EPMC12768466 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature